Coming October 2: SITC releases abstract titles with each presenting author’s institution (nearly 1,300 last year). We’ll add them to this guide once they’re out.

Regulatory science and biotech building at SITC 2026

Nov 4–8, 2026 Phoenix, AZ ~6k attendees Website

14 organizations at SITC 2026 present work in regulatory, policy & biotech building: 7 pharma and biotech companies, 4 suppliers and service providers, 2 cancer centres and hospitals and 1 government or non-profit body. Between them they bring 9 presentations to the program. Most represented: U.S. Food and Drug Administration (8 on the program), AstraZeneca (4 on the program), Marengo Therapeutics (2 on the program). 12 of them have their own page in this guide. As of Sep 29, 2026.

All 242 organizations at SITC 2026 →

Showing 1–10 of 14 organizations

Organization	SITC 2026 Attendance
U.S. Food and Drug Administration Silver Spring, MD
fda.gov Government & non-profit U.S. federal agency that regulates drugs, biologics and medical devices, including cancer immunotherapies.	Session Wed Nov 4 2:10pm–2:55pm Panel Discussion 1: Conversations with FDA Oncology Leaders on Hot Topics Encanto AB Regulatory Session Wed Nov 4 3:10pm–3:55pm Panel Discussion 2: Biomarker Discovery and Digital AI Encanto AB Biomarkers · AI & data Session Wed Nov 4 4:10pm–4:55pm Panel Discussion 3: Regulatory Framework for New IO Agents Encanto AB Regulatory · New agents Talk Fri Nov 6 2:45pm–3:00pm Part of Session 106b: Human Ex Vivo Models for Immunotherapy Testing: From Tumor Explants to Tumor-on-Chip From Conventional to New Approach Methodologies: Regulatory Considerations for Immuno-Oncology Safety Assessment 301A Regulatory · Models & tech
AstraZeneca Cambridge, United Kingdom
astrazeneca.com Large pharma Global biopharmaceutical company that discovers, develops and sells prescription medicines, with oncology among its main therapy areas.	Booth Exhibiting at Booth 801 Fri, Nov 610:00am–2:00pm · 5:00pm–7:00pmSat, Nov 710:00am–2:00pm · 6:00pm–8:10pm Workshop Wed Nov 4 2:00pm–5:00pm Biotech Regulatory Roundtable 2:00pm–2:10pmOpening Remarks: SITC Biotech Initiative: A Quest for 100 Novel Agents 2:10pm–2:55pmPanel Discussion 1: Conversations with FDA Oncology Leaders on Hot Topics 2:55pm–3:10pmNetworking Break 3:10pm–3:55pmPanel Discussion 2: Biomarker Discovery and Digital AI 3:55pm–4:10pmNetworking Break #2 4:10pm–4:55pmPanel Discussion 3: Regulatory Framework for New IO Agents 4:55pm–5:00pmClosing Remarks Workshop Wed Nov 4 2:10pm–2:55pm Panel Discussion 1: Conversations with FDA Oncology Leaders on Hot Topics Encanto AB Regulatory Session Wed Nov 4 4:10pm–4:55pm Panel Discussion 3: Regulatory Framework for New IO Agents Encanto AB Regulatory · New agents Talk Thu Nov 5 10:20am–10:30am Part of Session II: Immune Cell Engagers and Bispecifics From Bench to Bispecific: The Rilvegostomig Program at a Glance Valley of the Sun Ballroom New agents Session Thu Nov 5 12:00pm–1:30pm Collaborating with Industry Encanto AB Talk Thu Nov 5 4:30pm–5:00pm Part of Session II – Breakout Sessions Breakout Table: Interfacing with Industry (Biotech Grants) Encanto AB
Marengo Therapeutics Cambridge, MA
marengotx.com Biotech Clinical-stage biotech developing antibodies that target TCR V-beta chains to selectively activate T cell subsets against cancer.	Workshop Wed Nov 4 2:00pm–5:00pm Biotech Regulatory Roundtable 2:00pm–2:10pmOpening Remarks: SITC Biotech Initiative: A Quest for 100 Novel Agents 2:10pm–2:55pmPanel Discussion 1: Conversations with FDA Oncology Leaders on Hot Topics 2:55pm–3:10pmNetworking Break 3:10pm–3:55pmPanel Discussion 2: Biomarker Discovery and Digital AI 3:55pm–4:10pmNetworking Break #2 4:10pm–4:55pmPanel Discussion 3: Regulatory Framework for New IO Agents 4:55pm–5:00pmClosing Remarks Workshop Wed Nov 4 4:10pm–4:55pm Panel Discussion 3: Regulatory Framework for New IO Agents Encanto AB Regulatory · New agents Workshop Wed Nov 4 4:55pm–5:00pm Closing Remarks Encanto AB Session Thu Nov 5 12:00pm–1:30pm Setting Up a Successful Biotech (Midsize Pharma and Small Startups) Encanto AB Regulatory Workshop Thu Nov 5 5:00pm–9:00pm Launching Biotech Startups: Funding, Pitching, Partnerships 5:00pm–5:45pmWelcome Reception 5:55pm–6:55pmHigh-Impact Talks from Pharma Leaders 6:55pm–7:15pmPanel 7:00pm–7:50pmFinancing and Partnership Panel 8:00pm–9:00pmClosing Networking Reception
Merck & Co. Rahway, NJ
merck.com Large pharma Global pharmaceutical company, known as MSD outside the US and Canada, running a broad oncology research and clinical development program.	Booth Exhibiting at Booth 1228 Fri, Nov 610:00am–2:00pm · 5:00pm–7:00pmSat, Nov 710:00am–2:00pm · 6:00pm–8:10pm Session Wed Nov 4 3:10pm–3:55pm Panel Discussion 2: Biomarker Discovery and Digital AI Encanto AB Biomarkers · AI & data Talk Thu Nov 5 5:55pm–6:15pm Part of High-Impact Talks from Pharma Leaders Advancing External Innovation: Merck’s Oncology Strategy Regulatory Session Thu Nov 5 6:55pm–7:15pm Panel Session Fri Nov 6 3:55pm–5:30pm Biotech Session: The Next Generation of Off-the-Shelf IO Halls BC Cell therapy 3:55pm–4:10pmNext-gen T Cell Engagers 4:10pm–4:25pmIn vivo Cell Therapy Platforms for CancerEli Lilly and Company 4:25pm–4:40pmAllogeneic Cell TherapiesAllogene Therapeutics 4:40pm–5:00pm2 abstract presentations — titles not yet released 5:00pm–5:30pmIn Vivo - Ex Vivo DebateKite Pharma, Massachusetts Institute of Technology, Roswell Park Comprehensive Cancer Center, Azalea Therapeutics
Bristol Myers Squibb Princeton, NJ
bms.com Large pharma Global pharmaceutical company whose immuno-oncology medicines include the checkpoint inhibitors nivolumab and ipilimumab.	Talk Thu Nov 5 1:45pm–1:55pm Part of Session III: ADC/iADC Iza-bren: BMS's First Bispecific ADC, and Pumitamig, the PD-L1×VEGF-A Bispecific Antibody Valley of the Sun Ballroom New agents Talk Thu Nov 5 6:35pm–6:55pm Part of High-Impact Talks from Pharma Leaders BMS’s Approach to Scientific Opportunity and Strategic Partnership Regulatory Session Thu Nov 5 6:55pm–7:15pm Panel
Mount Sinai Hospital New York, NY
mountsinai.org Cancer centres & hospitals Teaching hospital of the Icahn School of Medicine at Mount Sinai in New York City.	Workshop Thu Nov 5 8:00am–4:15pm New Agents in Development and Emerging Technologies 8:00am–9:50amSession I: Cell Therapies and Technologies 10:05am–11:50amSession II: Immune Cell Engagers and Bispecifics 1:30pm–2:55pmSession III: ADC/iADC 3:10pm–4:15pmSession IV: Emerging Technologies – Incorporation into Clinical Trials Workshop Thu Nov 5 10:05am–11:50am Session II: Immune Cell Engagers and Bispecifics Valley of the Sun Ballroom New agents 10:05am–10:20amIntroduction/History/Approved Drugs/Almost Approved - Overview TalkJohnson & Johnson 10:20am–10:30amFrom Bench to Bispecific: The Rilvegostomig Program at a GlanceAstraZeneca 10:30am–10:40amUnlocking the Immune System: Advanced Combination Strategies for Cancer ImmunotherapyRegeneron 10:40am–10:50amIndustry Talk with Clinical DataGenmab 10:50am–11:00am(PD1xTGFb) 11:00am–11:10amInitial Clinical Results with T-cell Receptor (TCR)-based Bispecific T-cell Engagers (TCERs) Targeting PRAME and MAGEA4/8 in Advanced Solid TumorsImmatics 11:30am–11:50amDebate (Cell Therapy vs. Engagers)Johnson & Johnson Talk Thu Nov 5 3:40pm–3:55pm Part of Session IV: Emerging Technologies – Incorporation into Clinical Trials ARO/PACT Structure Valley of the Sun Ballroom Regulatory · Clinical Workshop Thu Nov 5 3:10pm–4:15pm Session IV: Emerging Technologies – Incorporation into Clinical Trials Valley of the Sun Ballroom Clinical 3:10pm–3:25pmIn vivo and Solid Tumor CAR-T Cell TherapiesUCSF 3:25pm–3:40pmAcademic and Industry Collaborations 3:40pm–3:55pmARO/PACT StructureMount Sinai Hospital
Iovance Biotherapeutics San Carlos, CA
iovance.com Biotech Develops and commercializes tumor-infiltrating lymphocyte (TIL) cell therapies for people with solid tumors.	Booth Exhibiting at Booth 700 Fri, Nov 610:00am–2:00pm · 5:00pm–7:00pmSat, Nov 710:00am–2:00pm · 6:00pm–8:10pm Session Wed Nov 4 4:10pm–4:55pm Panel Discussion 3: Regulatory Framework for New IO Agents Encanto AB Regulatory · New agents Workshop Fri Nov 6 1:10pm–1:25pm Tech Talk - Iovance Biotherapeutics 1 Exhibit Hall Presentation Stage Workshop Sat Nov 7 6:55pm–7:10pm Tech Talk - Iovance Biotherapeutics 2 Exhibit Hall Presentation Stage
Third Rock Ventures Boston, MA
thirdrockventures.com Investors Venture capital firm that founds, builds and invests in biotechnology companies.	Workshop Thu Nov 5 8:00am–4:15pm New Agents in Development and Emerging Technologies 8:00am–9:50amSession I: Cell Therapies and Technologies 10:05am–11:50amSession II: Immune Cell Engagers and Bispecifics 1:30pm–2:55pmSession III: ADC/iADC 3:10pm–4:15pmSession IV: Emerging Technologies – Incorporation into Clinical Trials Workshop Thu Nov 5 3:10pm–4:15pm Session IV: Emerging Technologies – Incorporation into Clinical Trials Valley of the Sun Ballroom Clinical 3:10pm–3:25pmIn vivo and Solid Tumor CAR-T Cell TherapiesUCSF 3:25pm–3:40pmAcademic and Industry Collaborations 3:40pm–3:55pmARO/PACT StructureMount Sinai Hospital Session Thu Nov 5 7:00pm–7:50pm Financing and Partnership Panel Regulatory
Mass Eye and Ear Boston, MA
masseyeandear.org Cancer centres & hospitals Harvard-affiliated specialty hospital for eye, ear, nose, throat, and head and neck care, part of Mass General Brigham.	Session Thu Nov 5 12:00pm–1:30pm Setting Up a Successful Biotech (Midsize Pharma and Small Startups) Encanto AB Regulatory Talk Fri Nov 6 4:00pm–4:15pm Part of Session 107d: Cytokine Engineering and Clinical Translation Anchored Cytokine Therapy for Cancer: Engineering the Next Generation of IO 301BC New agents
Roche Basel, Switzerland
roche.com Large pharma Swiss pharmaceutical and diagnostics company whose oncology portfolio includes the PD-L1 antibody atezolizumab and bispecific antibodies.	Talk Thu Nov 5 6:15pm–6:35pm Part of High-Impact Talks from Pharma Leaders Roche’s Approach to Advancing Oncology Regulatory Session Thu Nov 5 6:55pm–7:15pm Panel